2014
An Official American Thoracic Society Clinical Practice Guideline: Diagnosis, Risk Stratification, and Management of Pulmonary Hypertension of Sickle Cell Disease
Klings E, Machado R, Barst R, Morris C, Mubarak K, Gordeuk V, Kato G, Ataga K, Gibbs J, Castro O, Rosenzweig E, Sood N, Hsu L, Wilson K, Telen M, Decastro L, Krishnamurti L, Steinberg M, Badesch D, Gladwin M. An Official American Thoracic Society Clinical Practice Guideline: Diagnosis, Risk Stratification, and Management of Pulmonary Hypertension of Sickle Cell Disease. American Journal Of Respiratory And Critical Care Medicine 2014, 189: 727-740. PMID: 24628312, PMCID: PMC3983842, DOI: 10.1164/rccm.201401-0065st.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnemia, Sickle CellAnticoagulantsAntihypertensive AgentsAntisickling AgentsCardiac CatheterizationDecision Support TechniquesEchocardiography, DopplerErythrocyte TransfusionHumansHydroxyureaHypertension, PulmonaryPhosphodiesterase 5 InhibitorsRisk AssessmentSeverity of Illness IndexConceptsRight heart catheterizationTricuspid regurgitant velocitySickle cell diseasePulmonary vascular resistancePulmonary hypertensionManagement of patientsEvidence-based recommendationsStrong recommendationsWedge pressureVascular resistanceRisk stratificationWeak recommendationCell diseaseMortality riskOfficial American Thoracic Society Clinical Practice GuidelineSerum N-terminal pro-brain natriuretic peptide (NT-proBNP) levelsN-terminal pro-brain natriuretic peptide levelsElevated pulmonary artery wedge pressureNormal pulmonary capillary wedge pressurePro-brain natriuretic peptide levelsElevated tricuspid regurgitant velocityLow pulmonary vascular resistanceNT-pro-BNP levelsPhosphodiesterase-5 inhibitor therapyPulmonary artery wedge pressure
2010
Chronic Pain Is An Independent Predictor of Lower 6 Minute Walk Distance In Patients with Sickle Cell Disease: Results From Walk-PHaSST Study
Krishnamurti L, Goel R, Castro O, Barst R, Rosenzweig E, Sachdev V, Machado R, Gibbs S, Little J, Schraufnagel D, Girgis R, Morris C, Badesch D, Lanzkron S, Goldsmith J, Gordeuk V, Kato G, Gladwin M, Hassell K. Chronic Pain Is An Independent Predictor of Lower 6 Minute Walk Distance In Patients with Sickle Cell Disease: Results From Walk-PHaSST Study. Blood 2010, 116: 2658. DOI: 10.1182/blood.v116.21.2658.2658.Peer-Reviewed Original ResearchTricuspid regurgitant velocityAcute pain crisisSickle cell diseasePain crisisChronic painExercise capacityIndependent predictorsClinical trialsCell diseaseAcute sickle cell pain crisisSickle cell pain crisisMultivariable logistic regression analysisSickle cellsAcute pain ratingsHypertension clinical trialsTrials of sildenafilDouble-blind placeboEmergency department visitsGroup of patientsMinute walk distanceWeeks of treatmentNon-drug therapyFuture clinical trialsSignificant lower odds ratioLogistic regression analysisCigarette Smoking Is An Independent Predictor of Chronic Pain In Sickle Cell Patients: Results From the Walk-PHaSST Study
Goel R, Hassell K, Castro O, Barst R, Rosenzweig E, Sachdev V, Machado R, Gibbs S, Little J, Schraufnagel D, Girgis R, Morris C, Badesch D, Lanzkron S, Goldsmith J, Gordeuk V, Kato G, Gladwin M, Krishnamurti L. Cigarette Smoking Is An Independent Predictor of Chronic Pain In Sickle Cell Patients: Results From the Walk-PHaSST Study. Blood 2010, 116: 4804. DOI: 10.1182/blood.v116.21.4804.4804.Peer-Reviewed Original ResearchChronic SCD painSickle cell diseaseTricuspid regurgitant velocitySCD painChronic painPack yearsSmoking historyCigarette smokingCigarette smokersMedical historySCD genotypeSmall single-center studiesSix-minute walk distanceStepwise multivariable logistic regressionMultivariable logistic regression modelEfficacy of sildenafilEnvironmental smoke exposureFormer cigarette smokingMean pack yearsVaso-occlusive painAcute chest syndromeSingle-center studyAbnormal platelet activationMultivariable logistic regressionEffect sizeEvaluation Of Sildenafil Therapy For Patients With Sickle Cell Disease And Increased Tricuspid Regurgitant Velocity: Preliminary Results Of The Walk-PHaSST Trial
Machado R, Barst R, Yovetich N, Hassell K, Goldsmith J, Woolson R, Gordeuk V, Gibbs S, Little J, Kato G, Schraufnagel D, Krishnamurti L, Girgis R, Morris C, Berman-Rosenzweig E, Badesch D, Waclawiw M, Gladwin M. Evaluation Of Sildenafil Therapy For Patients With Sickle Cell Disease And Increased Tricuspid Regurgitant Velocity: Preliminary Results Of The Walk-PHaSST Trial. 2010, a2514-a2514. DOI: 10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a2514.Peer-Reviewed Original ResearchTricuspid regurgitant velocitySickle cell diseaseSildenafil therapyRegurgitant velocityCell diseasePatientsTherapyDiseaseTrials
2006
Elevation of tricuspid regurgitant jet velocity, a marker for pulmonary hypertension in children with sickle cell disease
Ambrusko S, Gunawardena S, Sakara A, Windsor B, Lanford L, Michelson P, Krishnamurti L. Elevation of tricuspid regurgitant jet velocity, a marker for pulmonary hypertension in children with sickle cell disease. Pediatric Blood & Cancer 2006, 47: 907-913. PMID: 16496290, DOI: 10.1002/pbc.20791.Peer-Reviewed Original ResearchConceptsElevated tricuspid regurgitant velocityTricuspid regurgitant velocitySickle cell diseaseAcute chest syndromePulmonary hypertensionCerebrovascular diseaseVasoocclusive crisisSCD patientsReticulocyte countCell diseaseType of SCDTricuspid regurgitant jet velocityLife-threatening complicationsObstructive sleep apneaPediatric SCD patientsRegurgitant jet velocityElevated reticulocyte countSignificant differencesNumber of echocardiogramsChest syndromeEchocardiographic evidenceOutpatient echocardiogramMean hemoglobinClinical characteristicsHydroxyurea therapy